# Examining the Merck Sharp & Dohme p53 peptidomimetic patent Landscape: A Personal Review
In the evolving field of peptide chemistry and molecular research, few areas command as much technical fascination as the developments surrounding the Merck Sharp & Dohme p53 peptidomimetic patent portfolio. As an enthusiast who keeps a close eye on library filings and intellectual property trends, I have spent significant time analyzing the documentation provided by organizations like WIPO and the USPTO. This deep dive focuses on the structural innovations detailed in these filings, particularly regarding complex macrocyclic designs.
When reviewing the technical specifications within these patents, such as *US2 These peptidomimetic macrocycles may be useful in anticancer therapies, particularly in combination with chemotherapy or radiation … 0250042961A1* or the *WO/2020/257153* filings, the focus shifts to the physical architecture of the molecules. The LSI terms often associated with this research include "protease-resistant" and "all-D configuration α-amino acids," which are critical for enhancing the bio-stability of these compounds.
What fascinates me, as someone who follows peptide synthesis closely, is the integration of the i, i+4 olefin staple. This technique is a variation of peptide engineering that locks the molecule into an alpha-helical conformation. By stabiliz Mar 20, 2013 · Merck, Sharp & Dohme, Corp. has filed for patents to protect the following inventions. This listing includes patent … ing the secondary structure, these peptidomimetic macrocycles are able to mimic natural protein-protein interactions without the rapid degradation that usually plagues linear sequences. The p53 activator function—specifically aimed at the inhibition of MDM2 and MDMX (also known as MDM4)—is the primary target of this biological engineering.
Why This Research Is Notable
From a personal experience standpoint, tracking the evolution of Merck Sharp & Dohme (MSD) patents provides a w Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in … indow into the transition from traditional chemical compounds to specialized, high-affinity peptide derivatives. Many of these inventions are designed for those exploring the *mechanism of action* in laboratory settings.
The patent landscape, which covers everything from substituted piperidines to complex macrocycles, is incredibly vast. If you are ever searching for a p53 inhibitor (Astex Pharmaceuticals/MSD) update, you wil Mar 30, 2023 · Patents Assigned to Merck Sharp & Dohme LLC METHODS FOR TREATING CANCER, AN INFECTIOUS DISEASE … l notice that the consistency of these patents shows a move toward higher cell permeability without membrane disruption. This is a crucial detail for anyone monitoring *SAR (Structure-Activity Relationship)* studies.
Addressing the Search Intent
* Patent search efficacy: When navigating these databases, it is vital to know that simply querying a company name isn't enough; filtering by specific titles like "P53 activator peptidomimetic macrocycles" yields more accurate results.
* Defining the scope: Many users are often confused about the difference between a standard peptide and a peptidomimetic. In my view, the distinction lies in the deliberate modification of the peptide backbone, which allows non-natural configurations to persist in challenging environments.
* Technological roadmap: By reviewing assignments to entities like Merck Sharp & Dohme LLC, we gain insight into the *priority date* and the developmental trajectory of these proprietary molecular architectures.
Concluding Thoughts on the Landscape
The rigor applied U.S. Patent Application for P53 PEPTIDOMIMETIC MACROCYCLES Patent to these patents—especially those detailing C-terminal extended p53 derivatives—demonstrates a high standard for intellectual property protection in biochemistry. The shift toward prot MY174452A - Substituted piperidines that increase p53 activity and … ease-resistant frameworks represents a massive leap forward in ensuring that modular chemical tools retain their integrity during re Dec 5, 2022 · Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal … search cycles.
For any researcher or enthusiast keeping track of these advancements, the provided technical documentation on sites like *Google Patents* serves as a primary source of truth. As we look ahead, the persistent development around these p53-directed peptidomimetic macrocycles will likely remain a pillar of research interest, provided we continue to focus on the granular data points that d P53 ACTIVATOR PEPTIDOMIMETIC MACROCYCLES - MERCK … efine their structural efficacy. Always rely on primary documentation when evaluating the specific design claims of these molecules, as the nuances found in the patent abstracts are where the true industry insight is hidden.
# Examining the Merck Sharp & Dohme p53 peptidomimetic patent Landscape: A Personal Review
In the evolving field of peptide chemistry and molecular research, few areas command as much technical fascination as the developments surrounding the Merck Sharp & Dohme p53 peptidomimetic patent portfolio. As an enthusiast who keeps a close eye on library filings and intellectual property trends, I have spent significant time analyzing the documentation provided by organizations like WIPO and the USPTO. This deep dive focuses on the structural innovations detailed in these filings, particularly regarding complex macrocyclic designs.
When reviewing the technical specifications within these patents, such as *US2 These peptidomimetic macrocycles may be useful in anticancer therapies, particularly in combination with chemotherapy or radiation … 0250042961A1* or the *WO/2020/257153* filings, the focus shifts to the physical architecture of the molecules. The LSI terms often associated with this research include "protease-resistant" and "all-D configuration α-amino acids," which are critical for enhancing the bio-stability of these compounds.
What fascinates me, as someone who follows peptide synthesis closely, is the integration of the i, i+4 olefin staple. This technique is a variation of peptide engineering that locks the molecule into an alpha-helical conformation. By stabiliz Mar 20, 2013 · Merck, Sharp & Dohme, Corp. has filed for patents to protect the following inventions. This listing includes patent … ing the secondary structure, these peptidomimetic macrocycles are able to mimic natural protein-protein interactions without the rapid degradation that usually plagues linear sequences. The p53 activator function—specifically aimed at the inhibition of MDM2 and MDMX (also known as MDM4)—is the primary target of this biological engineering.
Why This Research Is Notable
From a personal experience standpoint, tracking the evolution of Merck Sharp & Dohme (MSD) patents provides a w Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in … indow into the transition from traditional chemical compounds to specialized, high-affinity peptide derivatives. Many of these inventions are designed for those exploring the *mechanism of action* in laboratory settings.
The patent landscape, which covers everything from substituted piperidines to complex macrocycles, is incredibly vast. If you are ever searching for a p53 inhibitor (Astex Pharmaceuticals/MSD) update, you wil Mar 30, 2023 · Patents Assigned to Merck Sharp & Dohme LLC METHODS FOR TREATING CANCER, AN INFECTIOUS DISEASE … l notice that the consistency of these patents shows a move toward higher cell permeability without membrane disruption. This is a crucial detail for anyone monitoring *SAR (Structure-Activity Relationship)* studies.
Addressing the Search Intent
* Patent search efficacy: When navigating these databases, it is vital to know that simply querying a company name isn't enough; filtering by specific titles like "P53 activator peptidomimetic macrocycles" yields more accurate results.
* Defining the scope: Many users are often confused about the difference between a standard peptide and a peptidomimetic. In my view, the distinction lies in the deliberate modification of the peptide backbone, which allows non-natural configurations to persist in challenging environments.
* Technological roadmap: By reviewing assignments to entities like Merck Sharp & Dohme LLC, we gain insight into the *priority date* and the developmental trajectory of these proprietary molecular architectures.
Concluding Thoughts on the Landscape
The rigor applied U.S. Patent Application for P53 PEPTIDOMIMETIC MACROCYCLES Patent to these patents—especially those detailing C-terminal extended p53 derivatives—demonstrates a high standard for intellectual property protection in biochemistry. The shift toward prot MY174452A - Substituted piperidines that increase p53 activity and … ease-resistant frameworks represents a massive leap forward in ensuring that modular chemical tools retain their integrity during re Dec 5, 2022 · Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal … search cycles.
For any researcher or enthusiast keeping track of these advancements, the provided technical documentation on sites like *Google Patents* serves as a primary source of truth. As we look ahead, the persistent development around these p53-directed peptidomimetic macrocycles will likely remain a pillar of research interest, provided we continue to focus on the granular data points that d P53 ACTIVATOR PEPTIDOMIMETIC MACROCYCLES - MERCK … efine their structural efficacy. Always rely on primary documentation when evaluating the specific design claims of these molecules, as the nuances found in the patent abstracts are where the true industry insight is hidden.